Showing results for fx-322
Search instead for DX-322
🌐
Nih
pmc.ncbi.nlm.nih.gov › articles › PMC8279894
Improved Speech Intelligibility in Subjects With Stable Sensorineural ...
There are no approved pharmacologic therapies for chronic sensorineural hearing loss (SNHL). The combination of CHIR99021+valproic acid (CV, FX-322) has been shown to regenerate mammalian cochlear hair cells ex vivo. The objectives were to ...
🌐
Healthy Hearing
healthyhearing.com › home › report › experimental hearing loss drug fails to show benefit in clinical trial
Hearing loss drug FX-322 fails to show benefit in clinical trials
February 15, 2023 - Frequency Therapeutics halted its clinical trial for the experimental hearing loss drug FX-322 due to disappointing clinical trials results.
🌐
BioSpace
biospace.com › frequency-therapeutics-announces-topline-results-for-its-phase-2b-study-of-fx-322-for-the-treatment-of-sensorineural-hearing-loss
Frequency Therapeutics Announces Topline Results for its Phase ...
February 13, 2023 - Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced clinical results from the placebo-controlled Phase 2b study of FX-322 in individuals with acquired…
🌐
Springer
adisinsight.springer.com › drugs › 800050002
FX 322 - AdisInsight
January 11, 2024 - FX 322 is a small molecule drug, being developed by Frequency Therapeutics, for the treatment of sensorineural hearing loss (SNHL). FX 322 has been formulated
🌐
PubMed
pubmed.ncbi.nlm.nih.gov › 33617194
Improved Speech Intelligibility in Subjects With Stable Sensorineural ...
Delivery of FX-322 to the extended high-frequency region of the cochlea is well tolerated and enhances speech recognition performance in multiple subjects with stable chronic hearing loss.
🌐
Hearing Aid UK
hearingaid.org.uk › flash-audiology-news › could-the-fx322-drug-cure-hearing-loss
Could the FX 322 drug cure hearing loss? | Hearing Aid UK
04:10
The FX 322 gel is said to reverse hearing loss. Let's take a look at the science & facts behind this new drug for hearing loss. Is this really a cure?
Published: July 18, 2023
🌐
Yahoo! Finance
finance.yahoo.com › news › astellas-pharma-frequency-therapeutics-collaborate-073222267.html
Astellas Pharma and Frequency Therapeutics collaborate ...
August 13, 2024 - At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
🌐
Veeva
ctv.veeva.com › study › fx-322-in-adults-with-acquired-sensorineural-hearing-loss
FX-322 in Adults With Acquired Sensorineural Hearing Loss
April 21, 2023 - This is a Phase 2, prospective, randomized, double-blind, placebo-controlled, single-dose, multicenter study to evaluate the efficacy of FX-322, administered by intratympanic injection, in adults with acquired sensorineural hearing loss (SNHL).
🌐
Clinicaltrialsarena
clinicaltrialsarena.com › home › frequency’s fx-322 improves hearing function in trial subjects
Frequency’s FX-322 improves hearing function in trial subjects
April 10, 2019 - Frequency Therapeutics has reported positive data from a Phase I/II clinical trial of investigational drug FX-322 intended for hearing restoration.
🌐
YouTube
youtube.com › watch
Cure for Hearing Loss FOUND....& then LOST 😥 | FX-322 & ...
Enjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube.
Published: March 10, 2023
🌐
BioSpace
biospace.com › frequency-therapeutics-completes-enrollment-of-phase-2b-study-of-fx-322-for-the-treatment-of-sensorineural-hearing-loss
Frequency Therapeutics Completes Enrollment of Phase 2b Study of ...
October 12, 2022 - Frequency Therapeutics, Inc. today announced that it has completed enrollment of its placebo-controlled Phase 2b study of FX-322 in adults with acquired sensorineural hearing loss (SNHL).
🌐
WTWH Media
drugdiscoverytrends.com › home › drug discovery and development › frequency therapeutics shares plummet after fx-322 phase 2b failure
Frequency shares plummet after FX-322 Phase 2b failure
February 13, 2023 - Frequency Therapeutics shares were down more than 80% after the company announced the failure of the Phase 2b study for FX-322.
🌐
Veeva
ctv.veeva.com › study › fx-322-in-adults-with-stable-sensorineural-hearing-loss
FX-322 in Adults With Stable Sensorineural Hearing Loss
April 27, 2023 - This is a phase 2a single and repeat dose exploratory efficacy study of intratympanic FX-322 compared to placebo in healthy male and female adults with stable sensorineural hearing loss.
🌐
GEN
genengnews.com › home › topics › drug discovery › stockwatch: regeneron’s all ears for hearing loss drug developer
StockWatch: Regeneron’s All Ears for Hearing Loss Drug Developer
August 14, 2023 - Just last month, Korro Bio agreed to combine with Frequency Therapeutics through a reverse merger set to close in the fourth quarter. Frequency’s former lead candidate FX-322 in February failed a Phase IIb trial (FX-322-208; NCT05086276) in patients with acquired sensorineural hearing loss.
🌐
Albanyentandallergy
albanyentandallergy.com › clinical-research
Hearing Study | FX-322 | Albany ENT & Allergy Services
June 8, 2022 - (518) 701-2085 | Can a single dose medication potentially restore lost hearing? We’re working to find out. The physicians of Albany ENT and Allergy Services are helping to lead the charge and conducting clinical studies regarding FX-322, a new investigational drug that aims to activate and ...
🌐
Treble Health
treblehealth.com › fx-322-tinnitus-2021
The First Hearing Loss Cure? | FX-322 Update
April 18, 2023 - FX-322 is a new pharmaceutical research drug by Frequency Therapeutics aimed at finding a cure for hearing loss. This article will discuss updates in the drug’s development and its effectiveness in…
🌐
Astellas
astellas.com › en › news › 20801
Astellas and Frequency Therapeutics Enter into License Agreement ...
July 17, 2019 - Astellas Obtains the Exclusive Rights to Develop and Commercialize FX-322 in Ex-US Markets; Frequency Retains U.S. Rights Frequency will Receive $80 Million Upfront from Astellas with the Potential of up to $545 Million in Future Milestone Payments as well as Double-Digit Royalties
🌐
The Hearing Review
hearingreview.com › the hearing review › research › frequency therapeutics publishes fx-322 phase 1/2 results
Frequency Therapeutics Publishes FX-322 Phase 1/2 Results | The ...
February 24, 2021 - Frequency Therapeutics, Inc (Nasdaq: FREQ) announced the publication of its FX-322 Phase 1/2 study results in Otology & Neurotology.
🌐
Clinicaltrials
classic.clinicaltrials.gov › ct2 › show › NCT05086276
NCT05086276
Study record managers: refer to the Data Element Definitions if submitting registration or results information